Who is sponsoring NCT05905705?

NCT05905705 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT05905705?

Interventions in NCT05905705: Electroencephalography (EEG), Quantitative Measurements of Sleep Microstructure.

What condition does NCT05905705 study?

NCT05905705 studies Treatment Resistant Depression.

Is NCT05905705 still recruiting?

NCT05905705 is currently recruiting now. Last updated 12 March 2026.

Last reviewed 2026-03-12 · How we verify

NCT05905705: DNS-ECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

Recruiting now Last updated 12 March 2026

What this trial tests

trial testing Electroencephalography (EEG) in Treatment Resistant Depression in 50 participants. Currently enrolling.

Timeline

7 March 2023

Primary endpoint
31 July 2027

31 July 2027

Quick facts

Lead sponsor	Washington University School of Medicine
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	50
Start date	7 March 2023
Primary completion	31 July 2027
Estimated completion	31 July 2027
Sites	1 location across United States

Drugs / interventions tested

Electroencephalography (EEG)
Quantitative Measurements of Sleep Microstructure

Conditions studied

Treatment Resistant Depression — all drugs for Treatment Resistant Depression →

Sponsor

Washington University School of Medicine

Who can join

Adults 21 to 65, any sex, with Treatment Resistant Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Investigating the impact of electroconvulsive therapy on brain networks and sleep: an observational study protocol.
Kafashan M, Lebovitz L, Greenspan R, Zhao S, et al · · 2025 · cited 1× · PMID 40054874 · DOI 10.1136/bmjopen-2025-098859

Verify or expand the search:

Other trials of Electroencephalography (EEG)

Trials testing the same drug.

NCT07455682 — Auditory Processing in DOC Patients · not yet recruiting
NCT07110493 — Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements · NA · recruiting
NCT06867549 — Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II · Phase 2 · recruiting
NCT06813937 — Peripheral Magnetic Stimulation (PMS) Effects on Somatosensory Perception in Patients with Upper Limb Amputation · NA · recruiting
NCT04518254 — Contribution of L-Tyrosine to Human Decision Making in Stressful Situations · NA · completed

Other recruiting trials for Treatment Resistant Depression

Currently open trials in the same condition.

NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
NCT06938841 — Maintenance rTMS for Depression (Maitr-De) · NA · recruiting
NCT06236711 — Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD) · NA · active not recruiting
NCT05774665 — Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression · Phase 2 · active not recruiting
NCT06895863 — COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression · NA · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05905705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 12 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05905705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing